Veterinary/Animal Vaccines Market Analysis By Product (Attenuated Live, Inactivated, Subunit, DNA and Recombinant), By Animal Type (Companion Animal, Cattle, Poultry, Equine), And Segment Forecasts, 2018 - 2025

Industry Insights

The global veterinary/Animal vaccines market size was worth at USD 7.4 billion in 2016. Growing livestock population, rising animal husbandry coupled with commercialization of animal products are primarily boosting the market growth. Moreover, increasing investments by government and private players is supporting the growth of the market.

Developing countries have been experiencing rise in livestock population owing to increasing adoption of animal husbandry as a prime occupation.  Animal products contribute significantly in the country’s economic growth. For instance, livestock and crop accounted for 26.1 % of GVA (Gross Value Added). Similarly, milk production has shown a rise of 3.9 % in 2014 in India. Hence, the growing importance of animal products and increasing awareness regarding safe animal healthcare practices are propelling the demand for veterinary vaccines across the globe.

Advancements in formulations have resulted into the commercialization of modified products, which can be administered easily through oral route. Enhanced administration is escalating the adoption of vaccines for wild as well as domestic animals.

Animal Type Insights

Cattle segment accounted for the largest revenue share in 2016. Large revenue share is attributed to the factors such as rising livestock population, increasing government initiatives coupled with outbreak of diseases among cattle. The outbreak of some of the major viral respiratory tract infections in cattle and other chronic infections such as Enzootic Bronchopneu and Infectious Bovine Rhinotracheitis (IBR) are pushing the market growth.

Companion animal segment of the study is expected to exhibit the fastest growth during the forecast period. The factors such as constantly rising pet population coupled with the rising awareness regarding their health are propelling the growth of the segment globally. Adoption of vaccination for common life threatening diseases such as canine distemper, parvovirus and other canine viral diseases are propelling the growth of the segment share.

The development of subunit and modified live attenuated vaccines for the swine reproductive diseases are propelling the growth of swine segment. The constant R&D in order to develop novel vaccination solutions for various pig diseases coupled with the adoption of vaccination for swine are the factors expected to have a large impact on the segment growth.

Product Insights

Attenuated live vaccines segment accounted for the largest segment in 2016. Live attenuation is the oldest vaccination method used in veterinary field. This method is also under trial for development of additional applications. Some of these alternatives include the development of protein subunit vaccines for swine, which are given intramuscularly. These products aid in reducing mortality rate and improve the life span of disease-affected swine.

Along with the Transmissible Gastro Enteritis (TGEV) for and Porcine Epidemic Diarrhea (PED), the live attenuated products are also utilized for prevention of porcine respiratory and reproductive syndrome (PRRS). The threat of pathogenicity coupled with concern associated with improper attenuation resulting in critical issues such as residual virulence in the vaccinated animal is impeding market potential of inactivated segment.

Virulent organism by attenuation is used in cases such as local infection in lamb and ecthyma of sheep. Need for development of advanced, safer and efficient products are driving the research activities and are also expected to bring novel solutions over the forecast period.

Regional Insights

North America dominated the global market in 2016 and is expected to remain dominant throughout the forecast period. Rising incidence of canine disorders, in turn adoption of vaccination for the same coupled with the rising pet population in the U.S. are some of the key factors contributing to the expansion of market share of the region.

Europe is the second largest market for veterinary vaccines after North America. Rising production of veterinary products, improved animal husbandry practices, higher pet population are propelling the growth of the market in the region. Furthermore, collaborative initiatives of the government and private entities to promote improved animal health are the factors accelerating the adoption of veterinary vaccines in Europe.

Asia-Pacific is expected to show the fastest growth rate during the forecast period. Anticipated rise in the livestock population and the government initiatives especially in developing economies are some of the prime factors expected to boost the market growth in the region. The market is driven by high R&D expenditure by many major players combined with rising attempts for commercialization of veterinary pharmaceuticals and inoculations at tolerably low prices. 

Competitive Insights

Global Animal vaccines market is highly competitive. Key participants include Zoetis, Virbac Inc., Indian Immunological Limited, Heska Corp., Boehringer Inghlem, Bayer Pharma Ag, Merck Animal Health and Biogenesis Bago.

The key parameters affecting competitive nature include rapid adoption of veterinary preventive injections coupled with government involvement in bulk purchase of veterinary drugs. In addition, in an attempt to retain share and diversify the product portfolio, major players are frequently opting for mergers & acquisitions strategies.

Report Scope

Segments covered in the report

This report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global veterinary/Animal vaccines market on the basis of product, animal type and region:

• Product Outlook (Revenue, USD Million, 2014 - 2025)

  • Attenuated Live Vaccines

  • Inactivated Vaccines

  • Subunit Vaccines

  • DNA Vaccines

  • Recombinant Vaccines

• Animal Type Outlook (Revenue, USD Million, 2014 - 2025)

  • Companion Animal Vaccines

    • Canine

      • Distemper

      • Kennel cough (Parainfluenza)

      • Parvovirus

      • Canine herpes

      • Lyme Disease

    • Feline

      • Feline calicivirus

      • Peritonitis (FIP)

      • Feline FIV

  • Cattle Vaccines

    • BRSV

    • Enzootic Bronchopneu

    • IBR

    • BVD/MD

  • Poultry Vaccines

    • Bronchitis

    • Avian Influenza

    • Marek's Disease

    • Newcastle Disease

  • Pig Vaccines

    • Porcine reproductive disease

    • Swine Influenza

    • Swine Pneumonia

  • Equine Vaccines

    • Encephalomyelitis

    • Rhinopneumonitis

    • Influenza (Horse Flu)

• Regional Outlook (Revenue, USD Million, 2014 - 2025)

  • North America

    • U.S.

    • Canada

  • Europe

    • U.K.

    • Germany

  • Asia Pacific

    • India

    • China

  • Latin America

    • Brazil

    • Mexico

  • Middle East & Africa

    • South Africa